Sarat Chander

Partially Ablative Body Radiotherapy (PABR): A novel approach for pall... sciencedirect.com/science/articl… Kudos to the PABR team and @PeterMacRadOnc fellow @kelvinkenyu to get this to @RadiotherapyOn1 .Effective palliation for these unfortunate patients. Now onto the prospective trial!

@NiuSanford @OncoAlert Hopefully will result in practice change through MDTs

Great to see the updated BCLC guidelines include RT! RT now incorporated into most major guidelines for HCC (BCLC, AASLD, EASL, NCCN, others) & should be a standard of care option. Full link here: sciencedirect.com/science/articl… @OncoAlert

@anzsarcoma @WileyGlobal Dr Mathieu Gaudreault and Dr Adam Yeo from Medical Physics deserve due credit. Huge thanks to ANZSA!

A/Prof @saratchanderRO paper on automated planning for Lattice Radiation Therapy has been named one of the top 10% most-viewed papers of 2023 by Medical Physics. Part-funded by ANZSA, this work paves the way for more efficient, consistent treatment of complex tumours.

@gusviani @_ShankarSiva @OncoAlert @dr_khor

@gusviani @_ShankarSiva @OncoAlert There is this meta analysis published recently of TACE vs SABR. However patterns of referral and practice do not necessarily follow Randomised evidence in the real world.

🎙 Randomized Trial 🚨: SBRT vs. RFA for Recurrent Small HCC—Is It Time to Rethink Local Treatment? @OncoAlert 🔬 Study Highlights: 📌 Phase III trial, 166 👥 with recurrent HCC (≤5 cm, single lesion). 📌 Randomized to RFA (n=83) or SBRT (n=83) Key Outcomes: ✅ Local progression-free survival (LPFS): •2-year LPFS: 92.7% (SBRT)🏆 vs. 75.8% (RFA) (HR: 0.45, p=0.014). ✅ Progression-free survival (PFS): •Median PFS: 37.6 months (SBRT) vs. 27.6 months (RFA) (p=0.19).👌 ✅ Overall survival (OS): •2-year OS: 97.6% (SBRT) vs. 93.9% (RFA) (p=0.83).👌 ✅ Safety: Comparable acute and late adverse events.👍 📣 Implications for Practice: SBRT demonstrated ⬆️ local control while maintaining similar safety and OS compared to RFA.

@RadOncTMC @chatterji08 @sarbani30 @AROI_Since1976 Congratulations @sarbani30

Dr. Laskar, Dr. Sastri, and @chatterji08 with the newly appointed Chairman of ICRO, @sarbani30! Wishing her all the very best as she takes on this important role! @AROI_Since1976

@DrAndrewLoblaw @Sunnybrook @cristian_udo Drew hanging up his brachy boots (or gloves) is the biggest hint I suppose!

Stay tuned just wrapping up our @Sunnybrook analysis of 2 fraction HDR vs 2 fraction SBRT. @cristian_udo lead the charge!

@GenevieveLOOS12 @DrMHofman @ButeauJames @declangmurphy @sylvia_vandyk Well done @GenevieveLOOS12 for seeing it through. This series includes patients who were scanned before PSMA became a standard approach, 20 patients local uptake,12/13 who agreed to biopsy were positive, high validation!

Thanks to this fantastic team and great leadership! In case of biochemical recurrence after brachy for prostate cancer, PET PSMA delivers interesting information. authors.elsevier.com/c/1jsbR5TpjqSg… @DrMHofman @saratchanderRO @ButeauJames @declangmurphy @sylvia_vandyk

@JPoderMedPhys @KamravaMD Morton’s 2 fraction HDR mono therapy data continues to be the HDR standard in my opinion, our own retrospective outcomes from @PeterMacRadOnc support this too

@KamravaMD For mono it seems LDR is the way to go but would like to see a trial LDR vs fractionated HDR

Long term updates of 19x1 HDR. Morton - PMID 38879130 Hoskin - PMID 38997094 Each with different conclusions about single fx. What do you think?

Should ovarian tissue be harvested and stored before radiation to the pelvis in an adult woman? Can such a uterus successfully carry a pregnancy to term, even if I managed to spare only part of the uterus? Questions that arose in my mind in 2016. fertstertreports.org/action/showPdf…

Link to the paper now available authors.elsevier.com/c/1ig9ncA0-IVOd

Partially Ablative Body Radiotherapy (PABR): A novel approach for pall... sciencedirect.com/science/articl… Kudos to the PABR team and @PeterMacRadOnc fellow @kelvinkenyu to get this to @RadiotherapyOn1 .Effective palliation for these unfortunate patients. Now onto the prospective trial!

9 month scan of a 80 year old with synovial sarcoma overlayed on planning CT - shows a 78% reduction! Toxicity only fatigue! Purple is post PABR volume

@mikemejiamd @kelvinkenyu @PeterMacRadOnc @WarrenBacorro Wow back in action so soon @kelvinkenyu

⁦@kelvinkenyu⁩ back from ⁦@PeterMacRadOnc⁩ doing the #brachytherapy teaching rounds with ⁦@WarrenBacorro⁩

Thanks to @anzsarcoma,@PeterMacCC Foundation and Victorian Cancer Agency for ongoing support for the next stage of this !

@AusBrachy @kelvinkenyu @PeterMacRadOnc Second that as his fellowship supervisor!

#ABG2024 Hobart Rad Onc fellow Kelvin Yu @kelvinkenyu 🇵🇭 presenting on behalf of @PeterMacRadOnc urol/brachy team, the intricacies of salvage treatment. His fellowship has been so rewarding for us all. Sad to say goodbye.

Deepening the Philippine #radonc bench

#ABG2024 Hobart @angelo_tzovaras presenting proof of concept on the potential of 3D ultrasound to guide gynae brachytherapy. Perhaps IGABT can be more accessible in a regions with low resources. @PeterMacRadOnc @GlobalRadOnc @pixiepk1

@GenevieveLOOS12 🙏

Congratulations @saratchanderRO 🤩